These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32150469)

  • 1. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 2. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials.
    Ridker PM
    J Intern Med; 2019 May; 285(5):503-509. PubMed ID: 30472762
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Wieland H
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After ENHANCE: is more LDL cholesterol lowering even better?
    Stein EA
    Clin Chem; 2008 Jun; 54(6):940-2. PubMed ID: 18403568
    [No Abstract]   [Full Text] [Related]  

  • 10. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
    Martínez GJ; Celermajer DS; Patel S
    Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin Suppresses Interleukin Iβ Release in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals.
    Boland AJ; Gangadharan N; Kavanagh P; Hemeryck L; Kieran J; Barry M; Walsh PT; Lucitt M
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):509-517. PubMed ID: 29764192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
    Hansel B; Bruckert E
    Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
    Hoogeveen RM; Stroes ESG; Cornel JH
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory therapies for cardiovascular disease.
    Ridker PM; Lüscher TF
    Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise.
    Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing the cardiovascular prevention game. Results from a large clinical trial may mean a new era of super-low LDL targets and anti-inflammatory strategies.
    Harv Health Lett; 2009 Jan; 34(3):6. PubMed ID: 19172762
    [No Abstract]   [Full Text] [Related]  

  • 18. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
    Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
    Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
    Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.